Navigation Links
Gene Mutations May Boost Ovarian Cancer Survival: Study
Date:1/25/2012

By Kathleen Doheny
HealthDay Reporter

TUESDAY, Jan. 24 (HealthDay News) -- Genetic mutations known as BRCA1 and BRCA2 raise the risk of getting ovarian cancer, but new research shows that those same mutations may boost a woman's odds of surviving the deadly disease.

Women with invasive epithelial ovarian cancer who carry the mutations have a better prognosis than women without the genetic variations, according to an analysis of 26 previous studies. The BRCA2 carriers, in particular, had a better five-year survival rate.

"Our paper provides definitive evidence that BRCA1 and BRCA2 carriers have improvement in survival [compared to ovarian cancer patients without the mutations]," said Kelly L. Bolton, lead author of the new analysis and a medical student at the University of California, Los Angeles, David Geffen School of Medicine.

The study, which confirms previous findings, is published Jan. 25 in the Journal of the American Medical Association.

Nearly 23,000 women will get a diagnosis of ovarian cancer this year in the United States, and about 15,500 will die of it, according to the American Cancer Society. Epithelial ovarian cancer, the type Bolton focused on, occurs in the cells on the surface of the ovary.

Germline BRCA1 and BRCA2 mutations are found in up to 15 percent of women with this type of cancer. A germline mutation is a gene change in a reproductive cell that can be passed on to offspring.

Data from more than 1,213 ovarian cancer patients was included in the studies reviewed. Of these, 909 had BRCA1 mutations; 304 had BRCA2 variations.

The studies also included 2,666 women who did not have the genetic mutations.

At the five-year mark, 44 percent of the BRCA1 carriers and 52 percent of the BRCA2 carriers were alive, compared to 36 percent of those without the mutation.

Bolton said the survival differences remained after the researchers took into account such factors as the stage of the cancer and age, although it was less significant among women with a family history of ovarian and/or breast cancer.

Exactly how the mutations may improve survival is not known. However, Bolton and others speculate the BRCA1 or BRCA2 status may modify the response to platinum-based chemotherapy, a common treatment.

The new analysis will have important implications for future research and treatment of ovarian cancer, the authors said. Routine genetic screening of women with high-grade cancer might be warranted, they added.

Dr. Elizabeth Poynor, a gynecologic oncologist and pelvic surgeon at Lenox Hill Hospital in New York City, suggested the findings can help health care providers tailor treatment and more accurately counsel them regarding expected survival.

While not new, the information is valuable, Poynor said. "For a long time, we've known that individuals with BRCA1 or 2 actually have a better prognosis," she said. "This is not new information, it's expanded information. It's reinforcing what we already know."

More research is needed, the authors said, acknowledging some study limitations. For instance, the analysis lacked complete information on types of chemotherapy used, which might also have influenced survival.

Some co-authors reported consultancy fees from Complete Genomics Inc., a company engaged in gene sequencing, and from Merck Sharp & Dohme, Roche, Schering-Plough, Pfizer and other pharmaceutical firms.

More information

Learn how ovarian cancer is diagnosed at the American Cancer Society.

SOURCES: Kelly L. Bolton, Ph.D., medical student, University of California, Los Angeles, David Geffen School of Medicine; Elizabeth Poynor, M.D., gynecologic oncologist and pelvic surgeon, Lenox Hill Hospital, New York City; Jan. 25, 2012, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gene Mutations Linked to Thyroid Cancer Risk: Study
2. Massive DNA search uncovers new mutations driving blood cancer
3. Panel of melanoma mutations opens door to new treatment possibilities
4. Linking of mutations in 12 genes to ovarian cancer may lead to more effective prevention
5. Newly Found Gene Mutations May Aid Heart Treatments
6. Women With BRCA Mutations Get Cancer Diagnosis Earlier Than Before
7. Women who inherit BRCA gene mutations develop cancer earlier than their ancestors
8. Gene Mutations Identified in Uterine Fibroids
9. ADHD, Autism May Sometimes Share Gene Mutations
10. Elusive gene mutations found for malignant brain tumor
11. Scientists identify order of mutations that lead to cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Mutations May Boost Ovarian Cancer Survival: Study
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: